Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation

Abstract Background Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Reduced cardiovascular mortality and morbidity have been reported in non-HT patients treated with metformin. Given the high prevalence of type 2 diabetes mellitu...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Eilon Ram, Jacob Lavee, Alexander Tenenbaum, Robert Klempfner, Enrique Z. Fisman, Elad Maor, Tal Ovdat, Sergei Amunts, Leonid Sternik, Yael Peled
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2019-09-01
Sarja:	Cardiovascular Diabetology
Aiheet:	Heart transplantation Metformin Cardiac allograft vasculopathy Cardiovascular mortality
Linkit:	http://link.springer.com/article/10.1186/s12933-019-0925-y
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!